Obesity, Postoperative Nausea and Vomiting
Conditions
Interventions
Experimental group: 83 patients undergoing bariatric surgery will be given intravenous palonosetron 0.075 mg, before anesthesia induction. Control group: 83 patients undergoing bariatric surgery will
Drug
Sponsors
Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, UNESP
Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, UNESP
Eligibility
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Adult patients undergoing elective laparoscopic gastroplasty; both sexes; 20 to 65 years old; physical state I and II according to American Society of Anesthesiology (ASA); body mass index equal or higher than 35 kg/m2
Exclusion criteria
Exclusion criteria: Use of antiemetics for 48 hs before surgery; those with hiatal hernia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative nausea and/or vomiting incidence, verified by clinical observation and reported as yes or no, according to the presence of the symptom. Expected incidence of nausea and/or vomiting is 25% of patients in each group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total dose of dimenhydrinate (rescue medication) used, verified by its administration (yes or no), reported as the need of use. It is expected that 40 doses of dimenhydrinate in each group will be administered. | — |
Countries
Brazil
Contacts
Public ContactPaulo do Nascimento Junior
Faculdade de Medicina de Botucatu, UNESP
Outcome results
None listed